Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

NCT01347866 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

105

Enrollment

INDUSTRY

Sponsor class

Stopped Refer to Detailed Description for documentaion of Termination Statement.

Conditions

Advanced Cancer

Interventions

DRUG: PF-05212384
DRUG: PD-0325901
DRUG: PF-05212384
DRUG: irinotecan

Sponsor

Pfizer